항간질제가 태아의 선천기형 및 인지기능에 미치는 영향

키워드

참고문헌 (74)

1. Tomson T, "Teratogenic effects of antiepileptic medications", Neurol Clin, 27, pp.993~1002 (2009)
2. Gaily E, "Development and growth in children of epileptic mothers: a prospective controlled study", Acta Obstet Gynecol Scand, 70, pp.631~632 (1991)
3. Perucca E, "Birth defects after prenatal exposure to antiepileptic drugs", Lancet Neurol, 4, pp.781~786 (2005)
4. Holmes LB, "The teratogenicity of anticonvulsant drugs", N Engl J Med, 344, pp.1132~1138 (2001)
5. Battino D, "Management of epilepsy during pregnacy", Drugs, 67, pp.2727~2746 (2007)
6. Foldvary-Schaefer N, "Treatment of epilepsy during pregnancy in The treatment of epilepsy: principles and practice. 4th ed.", pp.715~718 (2006), Lippincott Williams and Wilkins
7. Yerby MS, "Teratogenicity and antiepileptic drugs: potential mechanisms", Int Rev Neurobiol, 83, pp.181~204 (2008)
8. Buehler BA, "Biochemical and molecular teratology of fetal hydantoin syndrome", Neurol Clin, 12, pp.741~748 (1994)
9. Ornoy A, "Valproic acid in pregnancy: How much are we endangering the embryo and fetus?", Reprod Toxicol, 28, pp.1~10 (2009)
10. Dansky LV, "Mechanisms of teratogenesis: folic acid and antiepileptic therapy", Neurology, 42(5), pp.32~42 (1992)
11. Yerby MS, "Management issues for women with epilepsy: neural tube defects and folic acid supplementation", Neurology, 61(2), pp.23~26 (2003)
12. Phiel CJ, "Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer and teratogen", J Biol Chem, 276, pp.36734~36741 (2001)
13. Fried S, "Malformation rates in children of women with untreated epilepsy", Drug Saf, 27, pp.197~202 (2004)
14. Tomson T, "Which drug for the pregnant woman with epilepsy?", N Engl J Med, 360, pp.1667~1669 (2009)
15. Meador K, "Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts", Epilepsy Res, 81, pp.1~13 (2008)
16. Tomson T, "Teratogenic effect of antiepileptic drugs", Seizure, 17, pp.166~171 (2008)
18. Cunnington M, "International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Effect of dose on frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study", Epilepsia, 48, pp.1207~1210 (2007)
19. Artama M, "Antiepileptic drug use of women with epilepsy and congenital malformations in offspring", Neurology, 64, pp.1874~1878 (2005)
20. Tomson T, "Teratogenic effects of antiepileptic medications", Neurol Clin, 27, pp.993~1002 (2009)
21. Morrow J, "Malformations risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register", J Neurol Neurosurg Psychiatry, 77, pp.193~198 (2006)
22. Holmes LB, "Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy", Neurology, 70, pp.2152~2158 (2008)
23. Holmes LB, "The AED (antiepileptic drug) pregnancy registry: a 6-year experience", Arch Neurol, 61, pp.673~678 (2004)
24. Wyszynski DF, "Increased rate of major malformations in offspring exposed to valproate during pregnancy", Neurology, 64, pp.961~965 (2005)
25. Holmes LB, "Hernandez-Diaz S. Pregnancy registries: larger sample sizes essential", Birth Defects Res, 82, pp.307~ (2008)
26. Vajda FJ, "The Australian register of antiepileptic drugs in pregnancy: the first 1002 pregnancies", Aust N Z J Obstet Gynecol, 47, pp.468~474 (2007)
27. Kondo T, "Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy", Epilepsia, 37, pp.1242~1244 (1996)
28. Samren EB, "Antiepileptic drug regimens and major congenital abnormalities in the offspring", Ann Neurol, 46, pp.739~746 (1999)
29. Fonager K, "Birth outcomes in women exposed to anticonvulsant drugs", Acta Neurol Scand, 101, pp.289~294 (2000)
30. Hvas CL, "Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birth weight", BJOG, 107, pp.896~902 (2000)
31. Long L, "Levetiracetam monotherapy during pregnancy: a case series", Epilepsy Behav, 4, pp.447~448 (2003)
32. Montouris G, "Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry", Epilepsy Behav, 4, pp.310~317 (2003)
33. Kaaja E, "Major malformations in offspring of women with epilepsy", Neurology, 60, pp.575~579 (2003)
34. Meischenguiser R, "Oxcarbazepine in pregnancy: clinical experience in Argentina", Epilepsy Behav, 5, pp.163~167 (2004)
35. Ornoy A, "Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy", Arch Dis Child, 75, pp.517~520 (1996)
36. ten Berg K, "Levetiracetam use and pregnancy outcome", Reprod Toxicol, pp.175~178 (2005)
37. Hunt S, "Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register", Neurology, 67, pp.1876~1879 (2006)
38. Hunt S, "Topiramate in pregnancy: preliminary experience from the UK epilepsy and pregnancy register", Neurology, 71, pp.272~276 (2008)
39. Meadow SR, "Anticonvulsant drugs and congenital abnormalities", Lancet, 2, pp.1296~ (1968)
40. Lindhout D, "Teratogenic effects of antiepileptic drugs: Implications for the management of epilepsy in women of childbearing age", Epilepsia, 35(4), pp.19~28 (1994)
41. Samren EB, "Antiepileptic drug regimens and major congenital abnormalities in the offspring", Ann Neurol, 46, pp.739~746 (1999)
42. Jentink J, "Valproic acid monotherapy in pregnancy and major congenital malformations", N Engl J Med, 362, pp.2185~2193 (2010)
43. Puho EH, "Drug treatment during pregnancy and isolated orofacial clefts in Hungary", Cleft Palate Craniofac J, 44, pp.194~202 (2007)
44. Arpino C, "Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE)", Epilepsia, 41, pp.1436~1443 (2000)
45. Canger R, "Malformations in offspring of women with epilepsy: a prospective study", Epilepsia, 40, pp.1231~1236 (1999)
46. Dolk h, "Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?", Neurology, 71, pp.714~722 (2008)
47. Hunt SJ, "Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy", Neurology, 72, pp.1108~1109 (2009)
48. Samren EB, "Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy", Epilepsia, 38, pp.981~990 (1997)
49. Kaneko S, "Congenital malformations due to antiepileptic drugs", Epilepsy Res, 33, pp.145~158 (1999)
50. Omtzigt JG, "The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort", Neurology, 42, pp.119~125 (1992)
51. Meador KJ, "In utero antiepileptic drug exposure: fetal death and malformations", Neurology, 67, pp.407~412 (2006)
52. Vajda FJ, "Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry", Eur J Neurol, 13, pp.645~654 (2006)
53. Mawer G, "Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate", Seizure, 11, pp.512~518 (2002)
54. Betts T, "Proactive preconception counseling for women with epilepsy: is it effective?", Seizure, 8, pp.322~327 (1999)
55. Kaaja E, "Major malformations in offspring of women with epilepsy", Neurology, 60, pp.575~579 (2003)
56. Vajda FJ, "The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months", J Clin Neurosci, 10, pp.543~549 (2003)
57. Harden CL, "Practice Parameter update: Management issues for women with epilepsy.Focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society", Neurology, 73, pp.142~149 (2009)
58. Pennell PB, "Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency", Neurology, 70, pp.2130~2136 (2008)
59. Tomson T, "Which drug for the pregnant woman with epilepsy?", N Engl J Med, 360, pp.1667~1669 (2009)
60. Koch S, "Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents", Epilepsia, 40, pp.1237~1243 (1999)
61. Oyen N, "Skjærven R. Maternal epilepsy and offspring's adult intelligence: a populationbased study from Norway", Epilepsia, pp.1731~1738 (2007)
62. Hirano T, "Physical and psychomotor development in the offspring born to mothers with epilepsy", Epilepsia, 45, pp.53~57 (2004)
63. Gaily E, "Distal phalangeal hypoplasia in children with prenatal phenytoin exposure: result of a controlled anthropometric study", Am J Med Genet, 35, pp.574~578 (1990)
64. Wide K, "Psychomotor development in preschool children exposed to antiepileptic drugs in utero", Acta Paediatr, 91, pp.409~414 (2002)
65. Losche G, "he psychological development of children of epileptic parents: II: the differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors", Acta Paediatr, 83, pp.961~966 (1994)
66. Gaily E, "Normal intelligence in children with prenatal exposure to carbamazepine", Neurology, 62, pp.28~32 (2004)
67. Holmes LB, "Intelligence and physical features of children of women with epilepsy", Teratology, 61, pp.196~202 (2000)
68. Adab N, "The longer term outcome of children born to mothers with epilepsy", J Neurol Neurosurg Psychiatry, 75, pp.1575~1583 (2004)
69. Vanoverloop D, "The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age", Neurotoxicol Teratol, 14, pp.329~335 (1992)
70. Scolnik D, "Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy", JAMA, 271, pp.767~770 (1994)
71. Reinisch JM, "In utero exposure to phenobarbital and intelligence deficits in adult men", JAMA, 274, pp.1518~1525 (1995)
72. Eriksson K, "Children exposed to valproate in utero: population based evaluation of risks and confounding factors for long-term neurocognitive development", Epilepsy Res, 65, pp.189~200 (2005)
73. Meador KJ, "Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs", N Engl J Med, 360, pp.1597~1605 (2009)
74. Harden CL, "Practice Parameter update: Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society", Neurology, 73, pp.133~141 (2009)

관련 논문AI추천